Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.
FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.
